FluGen, a Madison company founded in 2007 based on the research led by
UW-Madison avian flu expert Yoshihiro Kawaoka, has signed a licensing agreement
with the Wisconsin Alumni Research Foundation. The primary goal: to create a faster, more effective, less expensive way to
manufacture influenza vaccine. Since the 1930s, the standard for making flu vaccine has been that a team of
experts decides which flu strains to target, then chicken eggs are injected with
the viruses which are then grown for use in the vaccine. "It takes quite a bit of time to come up with that, and this year, they were
off," Paul Radspinner, FluGen president, chief executive and co-founder
said. Kawaoka, a veterinary medicine professor, and UW-Madison virologist Gabrielle
Neumann pioneered a new technique called reverse genetics that produces the
virus in cell culture instead of eggs. Large, stainless steel vats are used
"like those used in brewing beer," Radspinner said.
